SCHEMBL10399503

SCHEMBL10399503

Nc1ccc(SCCO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.57
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA7 P43166 1/20 0.57
CA13 Q8N1Q1 1/20 0.57
MAPK1 P28482 3/20 0.46
CYP3A4 P08684 3/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 6/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 2/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
THRB P10828 2/20 0.36
CASP1 P29466 2/20 0.36
HIF1A Q16665 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8637757 0.87 CA2 (0.61) CA2CA12CA1CA7CA13
SCHEMBL5096192 0.86 CA2 (0.59) CA2CA12CA1CA7CA13
SCHEMBL1808815 0.85 CYP3A4 (0.55) CA2CA12CA1CA7CA13
SCHEMBL14161357 0.85 CA2 (0.61) CA2CA12CA1CA7CA13
SCHEMBL9810746 0.83 CA2 (0.62) CA2CA12CA1CA7CA13
SCHEMBL7357654 0.83 CA2 (0.62) CA2CA12CA1CA7CA13
SCHEMBL8529367 0.80 CA2 (0.55) CA2CA12CA1CA7CA13
SCHEMBL12110770 0.80 MAPK1 (0.50) CA2MAPK1CYP3A4TSHRMEN1
SCHEMBL3900894 0.80 CA2 (0.55) CA2CA12CA1CA7CA13
SCHEMBL18656895 0.80 CYP3A4 (0.50) CA2CA12CA1CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 EP disclosed
US-20250214929-A1 SULPHONYL BENZENE DERIVATIVES AND METHODS FOR THE PREPARATION OF SULPHONYL BENZENE DERIVATIVES HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) 2025-07-03 US disclosed
WO-2024238570-A1 CDK2 INHIBITOR PYRAZOLOPYRIMIDINE COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
WO-2023209028-A1 SULPHONYL BENZENE DERIVATIVES AND METHODS FOR THE PREPARATION OF SULPHONYL BENZENE DERIVATIVES HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) 2023-11-02 WO disclosed
WO-2023209028-A1 SULPHONYL BENZENE DERIVATIVES AND METHODS FOR THE PREPARATION OF SULPHONYL BENZENE DERIVATIVES HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) 2023-11-02 WO disclosed
US-9796742-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-24 US disclosed
EP-2890460-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2017-02-22 EP disclosed
US-20160340375-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-24 US disclosed
US-20150210722-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2015-07-30 US disclosed
EP-2890460-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-07-08 EP disclosed
WO-2014033446-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-03-06 WO disclosed
CN-1948280-A Preparation method of aromatic amine UNIV DALIAN TECH (CN) 2007-04-18 CN disclosed
US-4964876-A Blue anthraquinone disperse dyes and mixtures of blue disperse dyes CIBA-GEIGY CORPORATION (US) 1990-10-23 US disclosed
EP-0344106-A2 Disperse blue dyes and mixtures of disperse blue dyes CIBA-GEIGY AG (CH) 1989-11-29 EP disclosed
EP-0137417-B1 PROCESS FOR THE PREPARATION OF AMINOBENZENE-ALKYLSULFONES OR AMINOBENZENE-ALKYLSULFOXIDES BAYER AG (DE) 1986-11-05 EP disclosed
EP-0137417-A1 Process for the preparation of aminobenzene-alkylsulfones or aminobenzene-alkylsulfoxides BAYER AG (DE) 1985-04-17 EP disclosed
US-3957860-A SULFAMIC ACID CIBA-GEIGY AG (CH) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214929-A1 SULPHONYL BENZENE DERIVATIVES AND METHODS FOR THE PREPARATION OF SULPHONYL BENZENE DERIVATIVES TST, BCR, ETV6 CA2 2831/4885CA12 1525/4885CA1 851/4885
US-20150210722-A1 KINASE INHIBITORS SYK, SRC, LYN CA2 2654/4885CA12 4798/4885CA1 4574/4885
US-20160340375-A1 KINASE INHIBITORS SYK, LYN, BTK CA2 2711/4885CA12 4815/4885CA1 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.